NCT03716856View on ClinicalTrials.gov

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

PHASE1UnknownINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 23, 2018

Primary Completion Date

June 23, 2020

Study Completion Date

June 23, 2023

Conditions
Refractory or Relapsed Multiple Myeloma
Interventions
GENETIC

CAR-BCMA T cells

"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."

DRUG

Fludarabine

Fludarabine is used for lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion

Trial Locations (1)

310006,

First Affiliated Hospital of Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

First Affiliated Hospital of Zhejiang University

OTHER